As Bioquell plc Surges, Should You Dump It To Invest In GlaxoSmithKline plc?

Here’s why this Fool would sell Bioquell plc (LON:BQE) and pick up GlaxoSmithKline plc (LON:GSK) instead.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Bioquell (LSE: BQE) announced today that it was looking for partners — inevitably, the stock rose more than 8% on the day, after an already impressive rally (+45%) so far this year. 

If you are invested in it, though, you may well wonder whether it is time to cash in and invest proceeds into GlaxoSmithKline (LSE: GSK), whose stock is down almost 14% since its 52-week high in April. 

Action At Bioquell

The sale of Bioquell’s testing unit TRaC Global for £44.5m earlier this year “represented a substantial premium to the then market capitalisation of the whole of Bioquell,” the group said on Monday, adding that the disposal unlocked substantial value for shareholders and also significantly simplified its corporate structure. 

Bioquell’s current market cap stands at £58m, which almost doubles the value of its revenues, yielding a forward net earnings multiple of 17x — based on the assumption that Bioquell would return to the black this year after small losses were reported in 2014. Trading multiples tell only one part of the story at Bioquell, of course.

Downside Vs Upside

Given the simplified structure, “increasing investor interest in the bio-pharmaceutical sector” and “heightened concerns of governments” around the world “in relation to antibiotic resistance“, the board of Bioquell has decided to carry out a strategic review of the group’s remaining biological contamination control business (60% of the group’s revenues) that may or may not lead to a combination with a larger partner. 

If the conclusion of the strategic review is to remain an independent business, the board’s intention is still to return a majority of the proceeds from the disposal of TRaC to Bioquell shareholders,” the group also added. Based on this information, upside appears to be very limited at 147p a share — where Bioquell currently trades. 

If I chose against investing in Bioquell, then, would I be wise to make a move for Glaxo instead? 

Glaxo: Lots Of Talk, Little Action 

As you might know, there are two big problems with Glaxo: firstly, its management team hasn’t lived up to expectations in recent times, I’d argue. Secondly, there has not been any meaningful update on its break-up, rumours of which have made the rounds for months and have been fuelled by bankers close to Glaxo and Glaxo managers themselves.

Still, I do not dislike Glaxo at 1,425p a share, where it currently trades. 

The stock offers little growth but a decent yield, given that Glaxo is expected to grow revenues and core profits just above inflation for a few years from now — yet its appealing forward yield above 5% could make up for little capital appreciation.  

So, one key question is just how safe is the dividend of an investment that looks a lot like a fully priced bond.

Glaxo’s financials are sound, its balance sheet and income statement show, but the cash flow statements point to the possibility that Glaxo may need to raise more debt to finance its dividend if projections for 2015 earnings aren’t met. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged Caucasian woman deep in thought while looking out of the window
Investing Articles

If I’d invested £1,000 in Lloyds shares at the start of the year, here’s what I’d have now

The stock market is unmoved, but Stephen Wright thinks last year’s record profits might give Lloyds shares a long-term boost.

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

I’ll snap up shares in this growth stock in March if others don’t get there first

This Fool says shares in this growth stock are stable, full of profit, and might be undervalued. But there are…

Read more »

Rainbow foil balloon of the number two on pink background
Investing Articles

My 2 top energy investment trust picks for a passive income

I'm aiming to buy more of these investment trusts for a passive income and the reasonably stable energy sector returns…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

5.5% dividend yield! Shares like these could be great for my retirement

Oliver Rodzianko thinks this company with a stellar dividend yield could be very useful when looking for income from his…

Read more »

Investing Articles

Should I buy this FTSE 250 stock as it soars back to the FTSE 100?

This FTSE 250 stock has rallied following its pandemic woes. This Fool thinks now could be a good time to…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

How I’d aim to transform an empty Stocks & Shares ISA into £1m of wealth!

There's never a better time to start investing in a Stocks and Shares ISA than today. Here's how I'd aim…

Read more »

Close up of manual worker's equipment at construction site without people.
Investing Articles

Investing £14,708 in this FTSE 100 stock could earn me £1,000 per year in passive income

Is a CMA investigation into anticompetitive practices the cloud cover Stephen Wright needs to start buying shares in a FTSE…

Read more »

Investing Articles

Despite rising 152% in a year, is Rolls-Royce’s share price still a bargain?

While Rolls-Royce’s share price has shot up recently, it still looks very undervalued against its peers, and the business looks…

Read more »